JOIN OUR TEAM
In 2020, the U.S. market saw four new brands previously sold as prescription drugs enter the nonprescription market: Pataday allergy eye drops Voltaren Arthritis Pain topical NSAID Advil Dual Action ibuprofen and acetaminophen pain reliever Sklice lice treatment The new switch approvals have signaled a willingness on the part of regulators to be less conservative when it comes to OTC access
As 2020 concludes, we are reflecting on the priority of health and safety, and how drastically different our everyday lives are compared to just eight months ago. We have seen major shifts toward the importance of immunity, with less emphasis on treatment of symptoms and more focus on prevention. We have a new perspective on the evolving role consumer healthcare products play in keeping us healthy. To help you put these major trends into perspective, below is a summary of our market studies and whitepapers that were
The U.S. OTC allergy relief market has seen a period of rapid growth over the past five years, and 2015 was no exception. GlaxoSmithKline’s Rx-to-OTC switch brand Flonase Allergy Relief entered the market in February 2015 and made a huge impact on the OTC market by adding previous prescription users to the category. The OTC
Estimated at over $24 billion at the manufacturers’ level in 2014, the U.S. nonprescription drugs market shows interesting opportunities for its players, posting growth in five out of the seven product classes tracked in Kline’s annual Nonprescription Drugs USA report. Let’s take a look at the top three drivers behind this market’s success: Rx-to-OTC switches
Growth of the U.S. nonprescription market is primarily driven by Rx-to-OTC switches as they bring former prescription users to the OTC market. Due to an increasingly favorable regulatory environment, Kline forecasts robust Rx-to-OTC switch activity over the next five years with several all new OTC categories emerging along with many new brands entering the market
With the publication of FDA’s NSURE (Nonprescription Safe Use Regulatory Extension) in February 2012, the pharmaceutical industry has been buzzing with potential for new switches, using unique approaches and technology to support the approval of new switches and safe use of consumer OTC medications. “There is excitement and new Rx-to-OTC switch possibilities being evaluated in
Infographic representing the U.S. Rx-to-OTC Switch Progression. Download the file here or copy paste the link: http://bit.ly/1cQBmWw
There have been signs recently indicating that the environment is becoming ripe for more Rx-to-OTC switches. Since we last reported on this topic in August 2013, we saw the approval of two additional first-in-class switches in categories that would have been thought of as challenging five years ago. One is the first incontinence medication available
With over half a century of market insights on the U.S. consumer healthcare market, Kline & Company expects that new paradigm shifts in regulations, retail, and technology will create new opportunities for medications to move along the Rx-to-OTC continuum and more growth prospects for the U.S. OTC market. Additionally, with the OTC medication market in
Given that many of the most obvious “switchable” drugs and categories have already taken place, opportunities that remain in moving medicines from prescription to nonprescription status require extensive research and novel approaches in order to gain FDA approval and be used by consumers safely and effectively without a prescription. There are several opportunities for new
